Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]

DRUG3 trials

Sponsors

University of Pennsylvania, Zuyderland Medisch Centrum, University Health Network, Toronto

Conditions

Kidney Transplant RecipientObesityObesity, MorbidWeight Gain

Phase 2

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

Not yet recruitingNCT06913023

University Health Network, TorontoKidney Transplant Recipient

Start: 2026-09-05End: 2029-12-30Target: 37Updated: 2026-09-16

Phase 4

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

CompletedNCT05548647

University of PennsylvaniaObesity

Start: 2022-07-26End: 2025-05-12Updated: 2026-08-03

Semaglutide 2.4mg for Low Responders After Bariatric Surgery

Not yet recruitingNCT06287307

Zuyderland Medisch CentrumObesity, Obesity, Morbid, Weight Gain

Start: 2024-05-31End: 2026-09-30Target: 152Updated: 2024-03-01